2020
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomesSafety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy
Gonzales P, Grieco A, White E, Ding R, Ignacio RB, Pinto-Santini D, Lama JR, Altice FL, Duerr A. Safety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy. PLOS ONE 2020, 15: e0228433. PMID: 32134956, PMCID: PMC7058313, DOI: 10.1371/journal.pone.0228433.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAntiretroviral therapyClinical adverse eventsAdverse eventsTransgender womenUse disordersDouble-blind randomized placebo-controlled trialMSM/transgender womenRandomized placebo-controlled trialART-naïve participantsPossibility of hepatotoxicityPlacebo-controlled trialSerious adverse eventsHIV-positive menMedication-assisted therapyProportion of subjectsAdverse event dataMultiple new medicationsOral naltrexoneStudy medicationTransaminase elevationPlacebo armNTX treatmentTreatment armsNew medications
2019
HIV-Related Stigma, Motivation to Adhere to Antiretroviral Therapy, and Medication Adherence Among HIV-Positive Methadone-Maintained Patients
Shrestha R, Altice FL, Copenhaver MM. HIV-Related Stigma, Motivation to Adhere to Antiretroviral Therapy, and Medication Adherence Among HIV-Positive Methadone-Maintained Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 80: 166-173. PMID: 30383588, PMCID: PMC6331231, DOI: 10.1097/qai.0000000000001891.Peer-Reviewed Original ResearchConceptsOptimal ART adherenceAntiretroviral therapyMethadone-maintained patientsMethadone maintenance treatmentART adherenceMaintenance treatmentHIV treatment outcomesHIV-positive patientsOpioid agonist therapyMultivariable logistic regressionHIV risk behaviorsExplanatory pathwaysAgonist therapySuboptimal adherenceMedication adherenceHIV treatmentTreatment outcomesHIV stigmaPatientsLogistic regressionHIVPrevention initiativesTherapyAdherenceSignificant correlates
2018
Factors Associated with HIV Viral Suppression Among Transgender Women in Lima, Peru
Rich KM, Wickersham JA, Huamaní J, Kiani SN, Cabello R, Elish P, Arce J, Pizzicato LN, Soria J, Sanchez J, Altice FL. Factors Associated with HIV Viral Suppression Among Transgender Women in Lima, Peru. LGBT Health 2018, 5: 477-483. PMID: 30874476, PMCID: PMC6306649, DOI: 10.1089/lgbt.2017.0186.Peer-Reviewed Original ResearchConceptsHIV-positive transgender womenViral suppressionTransgender womenUse disordersViral suppression ratesHIV viral suppressionMultivariable logistic regressionAdverse health outcomesSubstance use disordersAlcohol use disorderSevere drug useUse of drugsHIV statusSubstance disordersHigh burdenHigh prevalenceCondomless sexPsychiatric disordersAnal sexFactors AssociatedHealth outcomesDrug useHIV researchLogistic regressionLast partnerOpioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine
Mazhnaya A, Marcus R, Bojko MJ, Zelenev A, Makarenko I, Pykalo I, Filippovych S, Dvoriak S, Altice FL. Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 288-295. PMID: 30312275, PMCID: PMC8215524, DOI: 10.1097/qai.0000000000001827.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentHIV treatment cascadeTreatment cascadeAgonist treatmentIndependent factorsHepatitis C virus testingOpioid-dependent PWIDOpioid use disorderClinical care settingsLogistic regression modelsOAT coverageAntiretroviral therapyHIV careUNAIDS 90HIV preventionImproved outcomesTreatment strategiesCare settingsVirus testingNationwide studyPWIDUse disordersOAT expansionHIVCareExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomes
2017
Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study
Loeliger KB, Altice FL, Desai MM, Ciarleglio MM, Gallagher C, Meyer JP. Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study. The Lancet HIV 2017, 5: e96-e106. PMID: 29191440, PMCID: PMC5807129, DOI: 10.1016/s2352-3018(17)30209-6.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesHIV careViral suppressionTreatment outcomesPoor HIV treatment outcomesMore medical comorbiditiesPost-release linkagePredictors of linkageRetrospective cohort studyDetectable viral loadCase management servicesCase management dataTransitional case managementHealth care goalsAntiretroviral therapyMedical comorbiditiesCohort studyRetrospective cohortDays of releaseViral loadPharmacy databasePsychiatric comorbidityUS National InstitutesCase management needsHispanic ethnicityHepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study
Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. The Lancet Infectious Diseases 2017, 18: 215-224. PMID: 29153265, PMCID: PMC5860640, DOI: 10.1016/s1473-3099(17)30676-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntiviral AgentsChemopreventionCitiesComputer SimulationDisease Transmission, InfectiousFemaleHepatitis CHumansMaleMiddle AgedModels, StatisticalPrevalenceSubstance Abuse, IntravenousSurveys and QuestionnairesTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsBaseline HCV prevalenceHepatitis C virusHCV prevalenceInjection partnersPrevention strategiesTreatment coverageTransmission of HCVHepatitis C virus (HCV) treatmentHCV elimination strategySuccessful HCV treatmentC virus treatmentInjection drug usersHCV treatment coverageAdditional network memberHCV treatmentActing antiviralsC virusChronic infectionVirus treatmentDrug usersPrevalenceDrug abuseDrugsNational InstitutePreventionImplementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes
Mazhnaya A, Meteliuk A, Barnard T, Zelenev A, Filippovych S, Altice FL. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. International Journal Of Drug Policy 2017, 47: 187-195. PMID: 28811159, PMCID: PMC5918282, DOI: 10.1016/j.drugpo.2017.07.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCoinfectionFemaleGenotypeHealth ServicesHepacivirusHepatitis CHIV InfectionsHumansInterferon-alphaMalePolyethylene GlycolsProgram DevelopmentProgram EvaluationRecombinant ProteinsRibavirinRisk FactorsSex FactorsSofosbuvirSubstance Abuse, IntravenousSustained Virologic ResponseTreatment OutcomeUkraineYoung AdultConceptsSustained virologic responseHCV treatmentRisk groupsSVR ratesMedical recordsDirect acting antiviral medicationsComparable SVR ratesHCV genotype 3HCV prevalence estimatesHCV treatment servicesActing antiviral (DAA) medicationsCombination of sofosbuvirHigh-risk groupPatient-level outcomesProportion of participantsCommunity-based settingsDAA treatmentVirologic responseAntiviral medicationsHIV characteristicsHCV genotypesIndependent correlatesSVR dataFemale sexGenotype 3A qualitative assessment of an abstinence-oriented therapeutic community for prisoners with substance use disorders in Kyrgyzstan
Azbel L, Rozanova J, Michels I, Altice FL, Stöver H. A qualitative assessment of an abstinence-oriented therapeutic community for prisoners with substance use disorders in Kyrgyzstan. Harm Reduction Journal 2017, 14: 43. PMID: 28693573, PMCID: PMC5504733, DOI: 10.1186/s12954-017-0168-8.Peer-Reviewed Original ResearchConceptsUse disordersDrug useMethadone maintenance therapy programInjection drug useOpioid use disorderTherapeutic communitySubstance use disordersAddiction treatment outcomesCommunity staff membersLack of evidenceMethadone patientsTreatment optionsTreatment outcomesFuture treatmentTherapy programEvidence baseConvenience samplePatientsHigh rateLack of servicesPost-release programsPolicy documentsDisordersResultsOur analysisParticipant observationExtended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderFirst heavy drinking dayExtended-release naltrexoneXR-NTXDrinking daysPlacebo groupAlcohol consumptionDrinks/drinking dayPlacebo-controlled trialSerious adverse eventsDrinks/daySignificant differencesMonthly injectionsAdverse eventsHIV diseaseHIV outcomesTreatment armsAlcohol scoresMAIN OUTCOMEAlcohol consumption scoresUse disordersImprovement scoresDrinking outcomesNaltrexoneAssessment of an Innovative Voluntary Substance Abuse Treatment Program Designed to Replace Compulsory Drug Detention Centers in Malaysia
Khan F, Krishnan A, Ghani MA, Wickersham JA, Fu JJ, Lim SH, Dhaliwal SK, Kamarulzaman A, Altice FL. Assessment of an Innovative Voluntary Substance Abuse Treatment Program Designed to Replace Compulsory Drug Detention Centers in Malaysia. Substance Use & Misuse 2017, 53: 249-259. PMID: 28635521, PMCID: PMC5664175, DOI: 10.1080/10826084.2016.1267217.Peer-Reviewed Original ResearchConceptsCompulsory drug detention centersDrug useTreatment servicesVoluntary drug treatment centresTreatment programMethadone maintenance therapyEarly treatment outcomesCross-sectional convenience surveyDrug treatment centersSubstance abuse treatment programsDrug treatment programsAddiction treatment servicesSevere mental health issuesPast drug useMental health issuesNational Anti-Drug AgencyMaintenance therapyCare centerClient satisfactionTreatment outcomesTreatment centersDrug use levelsHealth servicesInvoluntary detentionSelf-reported satisfaction
2015
HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study
Vagenas P, Zelenev A, Altice FL, Di Paola A, Jordan AO, Teixeira PA, Frew PM, Spaulding AC, Springer SA. HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study. AIDS Care 2015, 28: 22-31. PMID: 26275122, PMCID: PMC4713253, DOI: 10.1080/09540121.2015.1062464.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAnti-HIV AgentsBlack or African AmericanBlack PeopleContinuity of Patient CareHealth Services AccessibilityHealthcare DisparitiesHIV InfectionsHomosexuality, MaleHumansInsurance, HealthKaplan-Meier EstimateMalePrisonersPrisonsRacial GroupsTreatment OutcomeYoung AdultConceptsBlack MSMHIV healthcare providersHIV treatment outcomesDisease management interventionsHIV/AIDS epidemicYoung Black MSMImpact of ageNon-black MSMHigher infection rateYoung HIVTreatment outcomesLarge cohortWorst HIVHIVHealth outcomesJail detaineesMale subgroupHealthcare providersInfection rateMulti-site studyMSMAIDS epidemicMenBlack menInterventionSex-Related Disparities in Criminal Justice and HIV Treatment Outcomes: A Retrospective Cohort Study of HIV-Infected Inmates.
Meyer JP, Cepeda J, Taxman FS, Altice FL. Sex-Related Disparities in Criminal Justice and HIV Treatment Outcomes: A Retrospective Cohort Study of HIV-Infected Inmates. American Journal Of Public Health 2015, 105: 1901-10. PMID: 26180958, PMCID: PMC4529767, DOI: 10.2105/ajph.2015.302687.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyViral suppressionSex-related differencesHigh prevalenceRisk scoreHIV treatment outcomesRetrospective cohort studyHIV viral suppressionLarge contemporary cohortSex-related disparitiesSex-specific interventionsCommunity-based treatmentWomen's higher prevalenceLogistic regression modelsCJ populationsTreatable comorbiditiesCohort studyHIV outcomesContemporary cohortTreatment outcomesHIVCJ involvementIncarceration durationOlder ageSignificant correlates
2014
An exploratory qualitative assessment of self-reported treatment outcomes and satisfaction among patients accessing an innovative voluntary drug treatment centre in Malaysia
Ghani MA, Brown SE, Khan F, Wickersham JA, Lim SH, Dhaliwal SK, Kamarulzaman A, Altice FL. An exploratory qualitative assessment of self-reported treatment outcomes and satisfaction among patients accessing an innovative voluntary drug treatment centre in Malaysia. International Journal Of Drug Policy 2014, 26: 175-182. PMID: 25577322, PMCID: PMC4291539, DOI: 10.1016/j.drugpo.2014.10.002.Peer-Reviewed Original ResearchConceptsCompulsory drug detention centersVoluntary drug treatment centresDrug treatment centersTreatment centersTreatment-based approachExploratory qualitative assessmentDrug treatment programsPositive patient experienceSelf-reported treatment outcomesAcute detoxificationAddiction needsMethadone treatmentCare centerTreatment successTreatment outcomesPatient's perspectivePatient experienceDrug usersHealthcare accessExplorative qualitative studyTreatment programPatientsAddiction rehabilitationConvenience samplePsychosocial programsOptimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate. JAMA Internal Medicine 2014, 174: 721-729. PMID: 24687044, PMCID: PMC4074594, DOI: 10.1001/jamainternmed.2014.601.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCD4 lymphocyte countViral suppressionHIV viral suppressionLymphocyte countObserved therapyRNA levelsBaseline HIV-1 RNA levelsMean HIV-1 RNA levelHuman immunodeficiency virus (HIV) treatmentHuman immunodeficiency virus managementHIV treatment outcomesRetrospective cohort studyAntiretroviral therapy regimensHIV-1 RNAPsychiatric disorder severityLogistic regression modelsCommunity-based resourcesDuration of incarcerationRace/ethnicityART regimenContinuous ARTPrescribed pharmacotherapyAntiretroviral therapyART regimens
2013
Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine
Bachireddy C, Soule MC, Izenberg JM, Dvoryak S, Dumchev K, Altice FL. Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine. Drug And Alcohol Dependence 2013, 134: 106-114. PMID: 24128379, PMCID: PMC3865106, DOI: 10.1016/j.drugalcdep.2013.09.020.Peer-Reviewed Original ResearchConceptsOpioid substitution therapyOpioid-dependent PWIDIsoniazid preventive therapyHealth-related qualityNeedles/syringesHIV-endemic regionsComposite scoreCross-sectional studyHealthcare quality indicatorsAntiretroviral therapyTuberculosis servicesPreventive therapySecondary outcomesHigher HRQoLMiddle-income countriesPrimary outcomePoor outcomeSubstitution therapyPotential confoundersTuberculosis treatmentHIV epidemicHIVHealth servicesPWIDOutreach settingsMethadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine
Morozova O, Dvoryak S, Altice FL. Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine. International Journal Of Drug Policy 2013, 24: e91-e98. PMID: 24360402, PMCID: PMC5553122, DOI: 10.1016/j.drugpo.2013.09.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidAntitubercular AgentsDelivery of Health Care, IntegratedDrug UsersFemaleHealth Knowledge, Attitudes, PracticeHeroin DependenceHumansInpatientsMaleMedication AdherenceMethadoneOpiate Substitution TreatmentProspective StudiesRisk FactorsTime FactorsTreatment OutcomeTuberculosisUkraineConceptsTB medication adherenceMethadone maintenanceTB treatmentMedication adherenceTreatment discontinuationMulti-drug resistant tuberculosisInpatient TB treatmentNumerous treatment challengesTB treatment completionOnly independent predictorOpioid-dependent patientsIndependent predictorsPrimary outcomeOpioid dependenceResistant tuberculosisMethadone treatmentTB facilitiesTreatment optionsDependent patientsTuberculosis treatmentTreatment completionTreatment challengesObservational studyMMT groupTreatment retentionContribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail
Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL. Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail. AIDS And Behavior 2013, 17: 118-127. PMID: 23673792, PMCID: PMC3818019, DOI: 10.1007/s10461-013-0506-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlcohol DrinkingAnti-Retroviral AgentsComorbidityCross-Sectional StudiesFemaleHIV InfectionsHumansLogistic ModelsMaleMedication AdherenceMiddle AgedPrisonersPrisonsSocioeconomic FactorsSubstance Abuse, IntravenousSubstance-Related DisordersTreatment OutcomeUnited StatesYoung AdultConceptsAntiretroviral medication adherenceSubstance use disordersMedication adherenceUse disordersEvidence-based drug treatmentHIV care providersHIV treatment engagementHIV treatment outcomesMedication-assisted therapyMulti-faceted interventionPaucity of evidenceDrug use severityAntiretroviral therapyPoor outcomePsychiatric comorbidityHIV treatmentTreatment outcomesDrug treatmentCare providersJail detaineesTreatment engagementUS sitesSubstance useVulnerable populationsUse severityPatterns of Homelessness and Implications for HIV Health After Release from Jail
Zelenev A, Marcus R, Kopelev A, Cruzado-Quinones J, Spaulding A, Desabrais M, Lincoln T, Altice FL. Patterns of Homelessness and Implications for HIV Health After Release from Jail. AIDS And Behavior 2013, 17: 181-194. PMID: 23657757, PMCID: PMC4625835, DOI: 10.1007/s10461-013-0472-6.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesTreatment outcomesNon-homeless patientsDrug addiction severityUse of alcoholVirological suppressionHIV healthHealth behaviorsJail detaineesMental illnessSubstance abuseAddiction severityMental healthCorrelates of homelessnessIllicit drugsStable housingHousing statusEffects of housingOutcomesHealthDifferent patternsHIVLongitudinal dataPatientsIllness